SAN JOSE, Calif., Oct. 25, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against canc

KING OF PRUSSIA, Pa., Oct. 25, 2019 /PRNewswire/ -- Recovery Centers of America ("RCA") announced an open application period for students seeking to apply for the

KING OF PRUSSIA, Pa., Oct. 25, 2019 /PRNewswire/ -- Universal Health Realty Income Trust (NYSE:UHT) announced today that for the three-month period ended September 30, 2019, reported net income was $4.7 million, or $.34 per diluted share, as compared to $4.4 million, or

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announced that the company is scheduled to present in the following investor conferences:

NEW YORK, Oct. 25, 2019 /PRNewswire/ -- TCI Co., Ltd. (stock code: 8436) was invited to join the 11th Anniversary of Climate Week NYC, one of the top global forums focusing on global climate action. Since 2009, Climate Week NYC has taken place every year and brings together international leaders from government, private sectors, and NGOs to discuss the poten

TOKYO, Oct. 25, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the European Commission (EC) has approved the oral once-daily therapy XOSPATA™ (gilteritinib) as a monotherapy for the treatment of adult patients with relapsed or refrac

BEIJING and SHANGHAI , Oct. 25, 2019 /PRNewswire/ -- Recently, Fountain Medical Development Limited ("Fountain Medical" or "Company") announced its $62 mm Series D round financing. The investment was led by Goldman Sachs, with Lilly Asia Ventures as co-investor. Proceeds of the Series D financing

STOCKHOLM, Oct. 25, 2019 /PRNewswire/ -- JANUARY 1 - SEPTEMBER 30, 2019 (compared with the corresponding period a year ago)       Net sales increased 9.0% to SEK 95,289m (87,388)           

INCLINE VILLAGE, Nev., Oct. 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that Harold E. Selick, Ph.D., Chairman of the Board of Directors of PDL BioPharma, has sent the following letter to Engine Capital, LP.October 24, 2019 Arnaud Ajdler

IRVINE, Calif., Oct. 24, 2019 /PRNewswire/ -- BIOLASE, Inc. (Nasdaq: BIOL), the global leader in dental lasers, today announced the pricing of an underwritten public offering of 7,820,000 shares of its common stock at a price to the public of $0.5750 per share.  In addition, BIOLASE has granted the underwriters a 30-day over-a